News and Events
SmartTots and IARS News, Press Releases and EventsPanda Symposium
SmartTots – Perspectives from the Front Lines
Millions of children undergo surgery annually. Recent studies suggest there may be reason for concern. This video, featuring Dr. Dean Andropoulos, Dr. Peter Davis, and Dr. Caleb Ing, provides a summary as to why research is needed and the type that is needed.
SmartTots to Help Make Anesthetics and Sedatives Safer for Children
Dr. Janet Woodcock, director of the Center for Drug Evaluation and Research at the Food and Drug Administration, and Dr. Michael Roizen, of the International Anesthesia Research Society, unveil a new partnership that aims to make anesthesia safer for children.
Pediatric Anesthesia Questions and Myths-Mayo Clinic
Dr. Randall Flick at Mayo Clinic “debunks myths” and answers common questions raised by parents in regard to anesthesia.
Search Announcement: Medical Officer
The International Anesthesia Research Society (IARS) is seeking candidates for the position of Medical Officer for the IARS-FDA SmartTots Public-Private Partnership. The position of Medical Officer provides expertise and support for the SmartTots research direction and the design of new research studies. This is a part-time position to be funded by a contract between the IARS and the candidate’s academic institution.
Anesthesia for Major Surgery in the Neonate
Perioperative risk of morbidity and mortality for neonates is significantly higher than that for older children and adults. At particular risk are neonates born prematurely, neonates with major or severe congenital heart disease, and neonates with pulmonary hypertension. Presently no consensus exists regarding the safest anesthetic regimen for neonates. Regional anesthesia appears to be safe, but does not reduce the overall risk of postoperative apnea.
Best Pharmaceuticals for Children Act (BPCA) Priority Releases 2020-2021 List of Needs in Pediatric Therapeutics
The National Institutes of Health (NIH) recently announced an updated BPCA Priority List of Needs in Pediatric Therapeutics. In an ongoing effort to improve the level of information on the safe and effective use of pharmaceuticals used to treat children, the BPCA requires that the NIH poll pediatric experts annually to identify the latest, highest priority needs.
HSP90 inhibitor 17AAG attenuates sevoflurane-induced neurotoxicity in rats and human neuroglioma cells via induction of HSP70
17AAG has been extensively studied for its antitumor effects that protect cells from lethal stress by maintaining protein stability. The role of 17AAG in sevoflurane-induced neuronal injury has never been studied. We aim to investigate the effect of 17AAG on sevoflurane-induced neurotoxicity in vivo and in vitro.
Effects of propofol on hippocampal neuron viability
In this study, we investigated the effects of different concentration of propofol on cell viability of hippocampal neurons and explored the possible mechanism.
Neuroprotective effects of dexmedetomidine against the ketamine-induced disturbance of proliferation and differentiation of developing neural stem cells in the subventricular zone
Recent years, the number of neonatal patients receiving surgery under general anesthesia is increasing. Previous studies have indicated that ketamine can disturb the proliferation and differentiation of developing neural stem cells (NSCs). Therefore, the safe use of ketamine in pediatric anesthesia has drawn great concern among anesthesiologists and children’s parents. Dexmedetomidine (DEX) is widely used in sedation, antianxiety and analgesia.